HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Régent L. Beaudet Daniel Doyle Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beaudet, R. L. Articles by Gauvin, C. Search for Related Content PubMed PubMed Citation Articles by Beaudet, R. L. Articles by Gauvin, C.

Ann Thorac Surg 1986;42:644-650
© 1986 The Society of Thoracic Surgeons

---

Articles

The Medtronic-Hall Cardiac Valve: 7 Years' Clinical Experience

From the Cardiovascular and Thoracic Surgery Service, Notre-Dame Hospital, University of Montreal, and the Cardiovascular and Thoracic Service, Royal Victoria Hospital, Montreal, Que, Canada

^* Address reprint requests to Dr. Beaudet, 1560E Sherbrooke St, Room G-1149, Notre-Dame Hospital, Montreal, Que, Canada H2L 4K8

Clinical information on the Medtronic-Hall valve prosthesis was obtained by reviewing the records of 379 patients, 164 of whom had aortic valve replacement (AVR), 163 of whom had mitral valve replacement (MVR), and 52 of whom had double valve replacement over 90 months (1,225 patient-years) (mean follow-up, 42.01 ± 1.3 months [± standard error]). Mean age was 53.8 ± 12 years. One hundred ninety-three patients (50.9%) had some type of concomitant operation, such as tricuspid annuloplasty, coronary artery bypass grafting, or resection of ascending aortic aneurysm. Ninety-one percent were in New York Heart Association (NYHA) Functional Class III or IV pre-operatively. Early mortality and late mortality were 7.7% (29 patients) and 13.5% (51 patients), respectively.

The actuarial survival at 7 1/2 years was 74.1 ± 2.7% for the total group and 69.0 ± 4.5% for those having AVR, 81.0 ± 3.2% for those having MVR, and 67.0 ± 8.9% for those having double valve replacement. All patients but 2 were maintained on a regimen of chronic anticoagulation with warfarin sodium. Twenty-six thromboembolic episodes occurred (2.1/100 patient-years): 13 after MVR (2.3/100 patient-years), 11 after AVR (2.1/100 patient-years), and 2 after double valve replacement (1.4/100 patient-years). Four thromboembolic episodes were fatal; no valve thrombosis occurred. There were no structural failures. Of the 350 late survivors, 92% were in NYHA Functional Classes I and II. Total valve-related complications have been minimal.

Our 7 1/2-year experience with the Medtronic-Hall valve prosthesis reveals a low thromboembolic rate of 2.1/100 patient-years in anticoagulated patients, a well-engineered and resistant valve structure, an acceptable hemolysis, and an acceptable rate of valve-related complications.

This article has been cited by other articles:

				A. E. Fiane, O. R. Geiran, and J. L. Svennevig Up to eight years' follow-up of 997 patients receiving the CarboMedics prosthetic heart valve Ann. Thorac. Surg., August 1, 1998; 66(2): 443 - 448. [Abstract] [Full Text] [PDF]

				C. E.E. Kuntze, E. H. Blackstone, and T. Ebels Thromboembolism and mechanical heart valves: a randomized study revisited Ann. Thorac. Surg., July 1, 1998; 66(1): 101 - 107. [Abstract] [Full Text] [PDF]

				S. Aoyagi, A. Oryoji, Y. Nishi, K. Tanaka, K. Kosuga, and K. Oishi Long-term results of valve replacement with the St. Jude Medical valve J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1021 - 1029. [Abstract] [Full Text]

				J. M. Kratz, F. A. Crawford, R. M. Sade, A. J. Crumbley, and M. R. Stroud St. Jude prosthesis for aortic and mitral valve replacement: A ten-year experience Ann. Thorac. Surg., September 1, 1993; 56(3): 462 - 468. [Abstract] [PDF]

				R. J. Keenan, J. M. Armitage, A. Trento, R. D. Siewers, R. L. Hardesty, H. T. Bahnson, and B. P. Griffith Clinical experience with the Medtronic-Hall valve prosthesis Ann. Thorac. Surg., November 1, 1990; 50(5): 748 - 753. [Abstract] [PDF]

				J. L. Vallejo, J. M. Gonzalez-Santos, J. Albertos, M. J. Riesgo, M. E. Bastida, M. J. Rico, F. Gonzalez-Diego, and R. Arcas Eight years' experience with the Medtronic-Hall valve prosthesis Ann. Thorac. Surg., September 1, 1990; 50(3): 429 - 436. [Abstract] [PDF]

				J.F. Lopez, B. Bharadwaj, and S. Lal Experience with Hall-Kaster Valves Vascular and Endovascular Surgery, January 1, 1990; 24(1): 16 - 22. [Abstract] [PDF]